ATECH (PARENT) RESOLUTION CORP.: Nasdaq/NYSE listing notice — Akoustis Technologies receives Nasdaq delisting notice, trading to be suspended Dec 18

ATECH (PARENT) RESOLUTION CORP.

Received delisting notice from Nasdaq on Dec 17, 2024 due to failure to meet minimum bid price of $1.00 and Chapter 11 bankruptcy.
Company does not intend to appeal the delisting determination by the Nasdaq Hearings Panel.
Trading of common stock (AKTS) will be suspended from Nasdaq Capital Market at opening on Dec 18, 2024.
Nasdaq will file Form 25-NSE to remove the stock from listing and registration on Nasdaq.
Company warns equity holders that trading is highly speculative and expects no recovery in Chapter 11 cases.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

ATECH (PARENT) RESOLUTION CORP. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: delisting notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

December 17, 2024, Akoustis Technologies, Inc. (the “Company”) received written notice (the “Notice”) from the Office of General Counsel of The Nasdaq Stock Market (“Nasdaq”) indicating that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s shares from Nasdaq due to the Company’s failure to meet Nasdaq’s continued listing standards. As previously disclosed, the Company has not been compliant with the requirement under Nasdaq Listing Rule 5550(a)(2) to maintain a minimum bid price of $1.00 for continued listing on the Nasdaq Capital Market. Additionally, the Notice

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001213900-24-109749

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.